TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Hypnotherapy for Prevention of Relapse in Ulcerative Colitis: a Randomised, Single-blind, Controlled Clinical Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Inactive UC~* Age 16-75 years~* Minimum 1 year on Azathioprine or Mercaptopurine.~* Simple Colitis Activity Index (SCCAI) score \<3~* Baron's sigmoidoscopic score \<2 .~* In remission for at least 3 months~* No change to other maintenance therapy (including 5ASA) for at least 4 months~Exclusion Criteria:~* Use of prednisolone orally or topically, or of topical 5ASA for at least 3 months Antibiotics, warfarin, anti-diarrhoeal drugs, non-steroidal anti-inflammatory drugs (NSAIDs), aspirin \> 75 mg/day~* Herbal remedies~* Alcohol or drug abuse~* Pregnancy or breast feeding~* Female of child-bearing age not taking adequate contraception~* Participation in another drug trial in the previous three months~* Serious liver, renal, cardiac, respiratory, endocrine, neurological or psychiatric illness~* Already use relaxation techniques or computerized feedback

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Gut-focussed hypnotherapy (GFH). (Type: ACTIVE_COMPARATOR): Gut-focussed hypnotherapy (GFH).
- Educational sessions (Type: SHAM_COMPARATOR): Regular sessions to learn about UC from research nurse

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: BIO|CONCEPT.ECG-Library

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is able to understand the nature of the study and willing to provide written informed consent.~* Patient is willing and able to attend Holter ECG procedure following a visit~* History of at least one of the following conditions (established via ECG prior to enrollment):~(A) Patient with pacemaker/ICD and~1. Ventricular stimulation \> 30 % or~   (B) Patient either without pacemaker/ICD or with pacemaker/ICD, but without significant atrial and ventricular stimulation and at least one of the following:~2. Frequent Ventricular Extrasystoles (VES) (incl. Bigeminus) or~3. Atrioventricular Reentrant Tachycardia (AVRT)/Wolff-Parkinson-White (WPW) syndrome or~4. Atrioventricular Nodal Reentrant Tachycardia (AVNRT) or~5. Sinus Tachycardia at rest or~6. Atrial Flutter or~7. Any form of Ventricular Tachycardia (VT) or~8. Silent/Paroxysmal/persistent/permanent AF or~9. Brugada syndrome or~10. Long QT syndrome or~11. Right Bundle Branch Block (RBBB) or~12. Left Bundle Branch Block (LBBB) or~13. Myocardial Ischemia/Acute Myocardial Infarction or~14. Other abnormal QRS(T) complex, ST segment or T-wave morphology, i.e. any other QRS anomaly / ST segment elevation / ST segment Depression / T wave changes~Exclusion Criteria:~* Any condition which precludes the patient's ability to comply with the study requirements.~* Known allergy to patch electrodes.~* Pregnant or breast feeding.~* Less than 18 years old.~* Participation in another interventional clinical investigation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 3-channel Holter ECG recording for EPS patient (Type: OTHER): Patients participating in an EPS will undergo a 3-channel Holter ECG recording in parallel to the standard 12-channel Holter ECG recording during the EPS followed by an optional 24 h observation period
- 12-channel Holter ECG recording for non-EPS patients (Type: OTHER): Patients scheduled for a follow-up for their heart disease will undergo a 12-channel Holter ECG recording while participating in a Body Motion test followed by a 24 h observation period

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Usability of the Embrace Seizure Detection Watch in Children and Young Adults With Dravet Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Meeting all of the main study ZX008-1503 \[NCT02823145\] inclusion criteria~* Subject is willing to wear the Embrace watch on the wrist (alternatively ankle, if needed for younger children). Subjects are asked to wear the watch for as many hours of the day as possible and for the entire night, if possible, for the duration of the sub-study.~* Subject's parent/caregiver is willing to use the Alert App.~* Subject/subject's caregiver is willing to ensure that the Embrace watch remains within close proximity of the paired iPod Touch running the Empatica Alert app.~Exclusion Criteria:~* Subject has a known hypersensitivity to any of the Embrace device materials.~* Subject has a clinically significant condition, or has had clinically relevant symptoms or a clinically significant illness in the 4 weeks prior to Visit 1, other than epilepsy, that would negatively impact study participation, collection of study data, or pose a risk to the subject.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- ZX008 (Type: EXPERIMENTAL): ZX008 is supplied as an oral solution in a concentration of 2.5 mg/mL. Subjects will be titrated to an effective dose beginning with 0.2 mg/kg/day (maximum: 30 mg/day).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Sym004 in Combination With FOLFIRI in Metastatic Colorectal Cancer Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Main inclusion Criteria:~1. Male or female, at least 18 years of age at the time of informed consent~2. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1~3. Histologically or cytologically confirmed, locally advanced or metastatic colorectal cancer (CRC) that is documented to be without Kirsten rat sarcoma (KRAS) or neuroblastoma rat sarcoma (NRAS) gene mutations (i.e., tumors must express the KRAS and NRAS wild type \[WT\], exon 2, 3 and 4).~4. Failed (defined as radiologic progression) treatment for locally advanced or metastatic disease with first-line combination therapy of oxaliplatin and a fluoropyrimidine, with or without bevacizumab, during treatment or \< 3 months after the last dose of first-line therapy and within \< 3 months of C1/D1. Patients who discontinued first-line therapy due to toxicity may be enrolled provided progression occurred \< 6 months after the last dose of the first-line therapy regimen.~   or Failed (defined as radiologic progression) adjuvant therapy with combination therapy of oxaliplatin and a fluoropyrimidine during treatment or within \< 6 months after the last dose of oxaliplatin and within \< 6 months of C1/D1.~5. Eligible for FOLFIRI~6. Measurable disease according to RECIST v1.1~Main exclusion Criteria:~1. Prior therapy with anti-EGFR antibodies, anti-EGFR small molecule inhibitors or irinotecan (CPT-11)~2. Any antineoplastic agent (standard or investigational) within 4 weeks prior to C1/D1~3. Significant gastrointestinal abnormalities~4. Patients with a significant cardiovascular disease or condition~5. Abnormal hematologic, renal or hepatic function

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sym004 12 mg/kg + FOLFIRI (Type: EXPERIMENTAL): Phase 1b, Dose-Escalation: Dose Level 1
- Sym004 9 mg/kg + FOLFIRI (Type: EXPERIMENTAL): Phase 1b, Dose-Escalation: Dose Level -1
- Sym004 (RP2D) + FOLFIRI (Type: EXPERIMENTAL): Phase 2a, Dose-Expansion: Sym004 in the RP2D in combination with FOLFIRI

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Gabapentin on Chronic Irritability in Neurologically Impaired Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* male or female~* 1 month to 16 years of age at enrollment~* neurological impairment defined as subnormal (-2 S.D.) motor and/or cognitive ability from a variety of etiologies~* chronic irritability defined as symptoms suggesting pain to the child's caregiver recurrently over a 4-week of greater time period~* Subject must have an acceptable surrogate capable of giving consent on the subject's behalf~Exclusion Criteria:~* Children with resolved symptoms after treatment of identified sources of pain~* Identified potential source of irritability without adequate trial of appropriate management~* Ketogenic diet~* Renal insufficiency or failure~* Current treatment with gabapentin or pregabalin for another existing condition.

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- Gabapentin, then placebo (Type: EXPERIMENTAL): Participants first receive gabapentin 3 times per day, with varying dosing based on the protocol. After 34-38 days, a washout period of 3 days occurs, before then receiving the placebo dose for 32 days.
- Placebo, then Gabapentin (Type: EXPERIMENTAL): Participants first receive placebo 3 times per day. After 34-38 days, a washout period of 3 days occurs, before then receiving Gabapentin, with varying dosing based on the protocol, for 32 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Sentinel™ Trial: A Prospective Study Evaluating the Performance and Clinical Benefit of Personalized ctDNA-based MRD Testing to Detect Recurrence and Monitor Treatment Response in Patients With Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Study participants must meet all the inclusion criteria below to enroll:~1. Male or female participants ≥ 18 years of age;~2. Confirmed diagnosis of a stage 1-3 solid tumor;~3. Curative surgery or definitive therapy (e.g., chemoradiation, stereotactic body radiation therapy \[SBRT\]) completed \<5 years ago without any current evidence of radiographical or biochemical recurrence, or planned within 28 days of consent;~4. Surplus formalin fixed paraffin embedded tumor specimen available;~5. Able to tolerate venipuncture for blood draws;~6. Primary diagnosis is not glioma or CNS disease;~7. Both the tumor tissue sample and blood sample pass the quantity and quality parameters to allow for a successful MRD test result.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: RFA RCT for Pancreatic or Bile Duct Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~- Either gender greater than or equal to 18 years of age.~* Pancreatic cancer or cholangiocarcinoma unsuitable for surgical resection. Criteria of unresectability being based on 1) metastatic disease or 2) locally advanced. Subjects that are deemed to be unresectable will be determined by a surgeon or treating oncologist.~* Biliary obstruction~* Subjects capable of giving informed consent~* Life expectancy of at least 6 months~Exclusion Criteria:~- Exclusion Criteria~* Cardiac Pacemaker~* Patient unstable for ERCP or has failed ERCP (endoscopic retrograde cholangiopancreatography )~* Inability to give informed consent~* Uncorrected coagulopathy~* Pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Radiofrequency Ablation (EndoHbp probe) (Type: EXPERIMENTAL): Radiofrequency Ablation using EndoHPB Probe
- Stenting only (Type: ACTIVE_COMPARATOR): Stenting only

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Impact of Nebivolol Versus Metoprolol on Quality of Life

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult renal transplant recipients, men and women between 18 and 75 years of age, inclusive.~* Patients must be \> 3 months post-transplant.~* Patients must have stable renal function (stable renal function will be defined as those patients without infection or hospitalization \[for any reason\] over the past 30 days, and patients with \< 20% change in their serum creatinine over the past 30 days.~* Patients receiving corticosteroids must be receiving a daily dose of \< 7.5 mg of prednisone (or therapeutic equivalents based on glucocorticoid equivalency scale).~* All eligible patients must be receiving antihypertensive medication management which must include metoprolol tartrate or metoprolol succinate.~* Patients may be on more than one medication to control their hypertension. Use of any other FDA-approved antihypertensive agent is permitted.~* All eligible patients will either be at goal blood pressure (\<120/80 mmHg) or have Pre-hypertension (\<140/90 mmHg) or Stage I hypertension (\<160/100 mmHg) at the time of study inclusion.~* Patients who are able to comprehend and satisfactorily comply with protocol requirements.~* Patients who signed the written informed consent given prior to entering any study procedure.~Exclusion Criteria:~* Patients with Stage II/uncontrolled hypertension (\>159/99 mmHg).~* Patients with an easily identifiable etiology for fatigue (i.e. anemia, iron-deficiency, poor sleep patterns, etc.).~* Patients who have a medical condition that, in the Investigator's opinion, would expose them to an increased risk of a significant adverse event or interfere with assessments of safety and efficacy during the course of the trial (i.e. arrhythmia).~* Patients with any current malignancy, or any clinically significant hematological, endocrine, cardiovascular, hepatic, gastrointestinal or neurological disease (including any form of epilepsy). If there is a history of such disease but the condition has been stable for at least the past year and is judged by the investigator not to interfere with the patient's participation in the study, the patient may be included.~* Patients who are judged by the investigator to be unable or unlikely to follow the study protocol and complete all scheduled visits.~* Patients with any contraindications to beta blocker therapy as listed in the package labeling for both metoprolol succinate and nebivolol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Nebivolol (Type: ACTIVE_COMPARATOR): None
- Metoprolol Succinate (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Behavioral Interventions on Mechanisms of Pain Regulation and Hedonic Regulation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. age 21-60 years of age~2. English fluency~3. 20/20 vision with corrective lenses~4. current chronic, non-neuropathic back pain diagnosis determined by physician assessment~5. reporting pain ≥3 on 0-10 scale with opioid medication~6. current use of prescription opioids for ≥3 consecutive months~7. ability to understand study procedures and to comply with them for the entire length of the study~Exclusion Criteria:~1. Mindfulness experience (e.g., MBSR or shamatha/vipassana meditation)~2. psychosis~3. untreated, active suicidality in the past month~4. and severe non-opioid substance use disorder in the past year as assessed with the MINI~5. clinically unstable illness judged to interfere with treatment, and presence of facial/jaw pain~6. pregnancy~7. inability or unwillingness of individual to give written informed consent~8. physical characteristics that preclude neuroimaging or study procedures (e.g., metal implants, etc.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Mindfulness-Oriented Recovery Enhancement (Type: EXPERIMENTAL): Participants will attend a Mindfulness-Oriented Recovery Enhancement (MORE) group weekly for eight weeks.
- Support Group (Type: ACTIVE_COMPARATOR): Participants will attend a support group weekly for eight weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Androgel on Atherogenesis in Type 2 Diabetic Males With Hypogonadotrophic Hypogonadism

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Males with age 30-60 years inclusive.~* PSA \< 2.6 ng/ml or \< 3.75 ng/ml with a negative prostate biopsy in the last 6 months.~* IPSS ≤ 19. The lower age limit was decided on the fact that in our study on hypogonadotrophic hypogonadism in type 2 diabetic patients, the youngest subject was 31 years old. The upper age limit has been restricted to 60 to avoid including subjects with significant age-related declines in testosterone concentrations.Subjects on thiazolidinediones, statins, ACE inhibitors, angiotensin receptor blockers or antioxidants will be allowed as long as they are on stable doses of these compounds and the dosage in not changed during the study. Subjects on insulin, metformin or sulfonylureas can participate in the study, provided that minimal changes are made to the doses during the study~Exclusion Criteria:~* Coronary event or procedure (myocardial infarction, unstable angina, coronary artery bypass, surgery or coronary angioplasty) in the previous four weeks; 2)Hemoglobin A1c \>10%;~* h/o prostate carcinoma;~* Hepatic disease (transaminase \> 3 times normal) or cirrhosis;~* Renal impairment (serum creatinine \> 1.5);~* HIV or Hepatitis C positive status;~* Participation in any other concurrent clinical trial;~* Any other life-threatening, non-cardiac disease;~* Use of over the counter health supplements which contain androgens;~* Use of an investigational agent or therapeutic regimen within 30 days of study.~* Use of testosterone in the past~* Hematocrit \> 50%.

- Gender: MALE
- Minimum Age: 31 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- androgel (Type: EXPERIMENTAL): androgel
- placebo (Type: PLACEBO_COMPARATOR): placebo gel
- no treatment (Type: NO_INTERVENTION): eugonadal comparison arm

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Does N-Acetylcysteine Decrease Spontaneous Oxidation of Central Neural Dopamine in Parkinson's Disease?

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
* INCLUSION CRITERIA:~* PD diagnosed within the past 5 years~* Taking a monoamine oxidase (MAO) inhibitor~* Able to provide consent~* At least18 years old~EXCLUSION CRITERIA:~* Taking levodopa in any form~* Known allergy to NAC~* Already taking an anti-oxidant dietary supplement (e.g., Olive Leaf Extract, MitoQ)~* A condition that would increase risk from a lumbar puncture (e.g., symptomatic spinal stenosis or myoclonus)~* History of a post-spinal headache that required treatment with a blood patch~* On a prescribed anti-coagulant (e.g., Coumadin, Plavix)~* Pregnant or breast-feeding~* History of alcohol or drug abuse~* Any medical condition thatcould put subjects at increased risk. Potential participants are excluded who have evidence of bone marrow, liver, or kidney failure based on abnormal screening lab results.~* On a medication that could interfere with the scientific results. An example of an exclusionary drug is the catechol-O-methyltransferase inhibitor entacapone. Tricyclic anti-depressants are another type of exclusionary drug

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Healthy Volunteers (Type: EXPERIMENTAL): HVs who undergo 2 LPs as inpatients, with 48 hours between LPs and no NAC treatment
- PD Patients (Type: EXPERIMENTAL): Patient undergoes a lumbar puncture (LP) as an inpatient at the NIH Clinical Center to obtain cerebrospinal fluid (CSF) for assays of Cys-DA, 3,4- dihydroxyphenylacetic acid (DOPAC), and related biochemicals. The second LP is done after the patient has taken at least 5 doses of NAC (2 grams orally twice per day).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues